Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

Both regimens “can be considered standard chemotherapy options” for high-risk, HR-positive early breast cancer, said Sherko Kuemmel, MD, PhD.

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

High-dose intravenous vitamin C combined with standard chemotherapy significantly extends survival in patients with metastatic pancreatic cancer. Learn more.

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

This clinical trial includes a dose escalation phase followed by an expansion phase, evaluating the potential of Lixumistat, an inhibitor targeting metabolism, in combination with gemcitabine and ...

Baseline geriatric assessment vulnerabilities and quality of life scores correlate with overall survival in patients with ...

Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in ...

Immuneering (IMRX) announced a positive data update from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104, ...